Ceragenix Pharmaceuticals
Ceragenix Pharmaceuticals was a biopharmaceutical company focused on the development and commercialization of novel anti-infective drugs based on its proprietary ceragenin technology. The company was headquartered in Denver, Colorado.
History[edit]
Ceragenix Pharmaceuticals was founded in 2005. The company aimed to address the growing problem of antibiotic resistance by developing new classes of anti-infective agents. Ceragenix's technology was based on ceragenins, which are synthetic antimicrobial peptides designed to mimic the body's natural defense mechanisms.
Technology[edit]
Ceragenix's core technology revolved around ceragenins, also known as cationic steroid antibiotics (CSAs). These compounds are designed to target and disrupt the membranes of bacteria, fungi, and viruses. Unlike traditional antibiotics, ceragenins are less likely to induce resistance due to their unique mechanism of action.
Ceragenins[edit]
Ceragenins are small, amphipathic molecules that mimic the structure and function of antimicrobial peptides (AMPs). They are composed of a steroidal backbone with cationic groups that interact with the negatively charged components of microbial membranes, leading to membrane disruption and cell death.
Products[edit]
Ceragenix Pharmaceuticals developed several products based on its ceragenin technology, including:
- CSA-13: A ceragenin compound with broad-spectrum antimicrobial activity.
- EpiCeram: A topical cream for the treatment of atopic dermatitis and other skin conditions. EpiCeram was designed to restore the skin's natural barrier function.
Research and Development[edit]
The company conducted extensive research and development to explore the potential applications of ceragenins in various medical fields. This included studies on their efficacy against methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, and other drug-resistant pathogens.
Acquisition and Legacy[edit]
In 2010, Ceragenix Pharmaceuticals was acquired by Cellerate, LLC, a company specializing in wound care products. The acquisition allowed for the continued development and commercialization of ceragenin-based products.
See also[edit]
- Antimicrobial resistance
- Biopharmaceutical
- Antimicrobial peptides
- Atopic dermatitis
- Methicillin-resistant Staphylococcus aureus
References[edit]
External links[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
